The present investigations confirm and extend previous reports on the occurrence of cytochemical anomalies among the hemopoietic cells in preleukemia. The cytochemical patterns of the hemopoietic cells obtained from 19 patients suffering from a preleukemic disorder have been studied. The diagnostic value of the cytochemical examination using a panel of 10 different tests is emphasized. In a prospective study in 17 out of 25 patients, preleukemia had been correctly diagnosed. In 4 patients leukemia developed within 2–4 months from the diagnosis (‘imminent leukemia’), in 13 patients leukemia or smouldering leukemia developed between 4 and 25 months after the diagnosis (‘true preleukemia’). The cytochemical profiles of the hemopoietic cells of the latter have been compared with those of 14 patients suffering from aplastic anemia. In preleukemia the blasts did not exceed 3% of the nucleated bone marrow cells. The clinical value of the diagnosis ‘preleukemia’ is discussed as well as the prognosis and the possible therapeutic approaches.

Keywords:
Preleukemia, Sideroblastic anemia, Acute myelogenous leukemia, Cytochemistry, Hemopoietic maturation defects
This content is only available via PDF.
© 1978 S. Karger AG, Basel
1978
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.